@prefix this: <http://www.tkuhn.ch/bel2nanopub/RACdsCZjq-Hs33PeslydQZCEtD9OqANLl6wHbq1x58T40> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RACdsCZjq-Hs33PeslydQZCEtD9OqANLl6wHbq1x58T40#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix schem: <http://resource.belframework.org/belframework/20131211/namespace/selventa-legacy-chemicals/> .
@prefix RNA: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_33697> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix do: <http://disease-ontology.org/term/DOID:> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: hgnc:1043;
    a RNA: .
  
  sub:_2 occursIn: do:1240, species:9606;
    rdf:object sub:_1;
    rdf:predicate belv:increases;
    rdf:subject schem:Tretinoin;
    a rdf:Statement .
  
  sub:assertion rdfs:label "a(SCHEM:Tretinoin) -> r(HGNC:BGLAP)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_4;
    pav:version "20131211" .
  
  sub:_3 prov:value "To monitor the ability of ATRA and VD to activate the genetic program underlying monocytic differentiation in the M2 cellular context, we have investigated the expression of VD-responsive genes (Fig. 8) such as HMSE-1, CD14, and hOC by RT-PCR and the expression of genes controlled by a functional VDRE, such as p21waf-1 (51) , or RARE, such as E3 (52) , IRF-1 (53) and p21waf-1 (68) , by Northern blot analysis after different times of ATRA or VD treatment. Fig. 8 shows that both ATRA and VD treatment of Kasumi-1 cells causes a rapid induction of HMSE-1, CD14, and hOC expression, demonstrating VDR involvement in ATRA-dependent monocytic differentiation of M2-type blast cells.";
    prov:wasQuotedFrom pubmed:10446999 .
  
  sub:_4 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:10446999;
    prov:wasDerivedFrom beldoc:, sub:_3 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:31:31.563+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}